---
title: "Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298292974.md"
description: "iSpecimen shares surged 27.9% in pre-market trading after announcing a $4.5 million acquisition of Foldlab AI assets. Other notable movers include CEA Industries, which gained 81.3%, and Focus Universal, which plummeted 51.2%. The pre-market session also saw significant gains for GMEX Robotics and BrenX, while major declines were recorded by Dyne Therapeutics and Novartis AG following trial results."
datetime: "2026-09-08T08:44:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298292974.md)
  - [en](https://longbridge.com/en/news/298292974.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298292974.md)
generator: "portal-rs"
---

# Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

Shares of **iSpecimen Inc** (NASDAQ:ISPC) rose sharply in pre-market trading after the company announced plans to acquire Foldlab AI assets for $4.5 million, including AI models, software and intellectual property.

iSpecimen shares jumped 27.9% to $1.97 in pre-market trading.

Here are some other stocks moving in pre-market trading.

### Gainers

-   **CEA Industries Inc** (NASDAQ:BNC) gained 81.3% to $6.33 in pre-market trading after adding 6% on Friday.
-   **GMEX Robotics Corp** (NASDAQ:GMEX) rose 48.6% to $1.10 in pre-market trading after falling 5% on Friday.
-   **BrenX Ltd.** (NASDAQ:BRNX) gained 25% to $2.80 in pre-market trading after falling around 26% on Friday.
-   **Wing Yip Food Holdings Group** (NASDAQ:WYHG) gained 19.7% to $4.86 in pre-market trading.
-   **OceanPal Inc** (NASDAQ:SVRN) rose 19.1% to $10.80 in pre-market trading after dipping 14% on Friday.
-   **Super League Enterprise, Inc**. (NASDAQ:SLE) rose 17.1% to $4.59 in pre-market trading after gaining 11% on Friday.
-   **Boxabl Inc**. (NASDAQ:BXBL) rose 12.6% to $4.90 in pre-market trading.
-   **Singularity Future Technology Ltd.** (NASDAQ:SGLY) gained 9.1% to $1.5055 in pre-market trading following a 6% decline on Friday.
-   **Waterdrop Inc**. (NYSE:WDH) gained 7.2% to $1.1197 in pre-market trading. Waterdrop will report second quarter financial results on Sept. 8.

### Losers

-   **Focus Universal Inc** (NASDAQ:FCUV) tumbled 51.2% to $8.30 in pre-market trading after dipping around 14% on Friday.
-   **Dyne Therapeutics, Inc** (NASDAQ:DYN) fell 35.5% to $15.64 in pre-market trading. Dyne Therapeutics will present preclinical data for multiple development candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting.
-   **bioAffinity Technologies In**c (NASDAQ:BIAF) fell 22.5% to $11.82 in pre-market trading after gaining 19% on Friday.
-   **Onconetix Inc** (NASDAQ:ONCO) declined 21.6% to $0.80 in pre-market trading after jumping 38% on Friday.
-   **Turbogen Ltd** (NASDAQ:TRBG) fell 19.4% to $5.91 in pre-market trading after dipping 38% on Friday.
-   **CL Workshop Group Ltd – ADR** (NASDAQ:NWGL) fell 17.3% to $1.05 in pre-market trading after gaining 23% on Friday.
-   **Scienjoy Holding Corp** (NASDAQ:SJ) fell 16.3% to $0.87 in pre-market trading. Scienjoy recently announced plans to buy 29.9% of Leader Education for about $13.1 million.
-   **Sarepta Therapeutics Inc** (NASDAQ:SRPT) fell 15.6% to $19.00 in pre-market trading. Sarepta Therapeutics, last month, posted upbeat quarterly results.
-   **Novartis AG** (NYSE:NVS) fell 12.7% to $139.56 in pre-market trading after the company disclosed that the pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint.
-   **OFA Group** (NASDAQ:OFAL) fell 11.7% to $0.69 in pre-market trading. OFA Group shares jumped 15% on Friday after the company announced its QikBIM platform logged more than 280,000 views and thousands of new followers in its first 90 days.

*Photo via Shutterstock*

### Related Stocks

- [GMEX.US](https://longbridge.com/en/quote/GMEX.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [FCUV.US](https://longbridge.com/en/quote/FCUV.US.md)
- [ISPC.US](https://longbridge.com/en/quote/ISPC.US.md)
- [BNC.US](https://longbridge.com/en/quote/BNC.US.md)
- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)
- [BRNX.US](https://longbridge.com/en/quote/BRNX.US.md)
- [WYHG.US](https://longbridge.com/en/quote/WYHG.US.md)
- [SVRN.US](https://longbridge.com/en/quote/SVRN.US.md)
- [SLE.US](https://longbridge.com/en/quote/SLE.US.md)
- [BXBL.US](https://longbridge.com/en/quote/BXBL.US.md)
- [SGLY.US](https://longbridge.com/en/quote/SGLY.US.md)
- [WDH.US](https://longbridge.com/en/quote/WDH.US.md)
- [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md)
- [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md)
- [TRBG.US](https://longbridge.com/en/quote/TRBG.US.md)
- [NWGL.US](https://longbridge.com/en/quote/NWGL.US.md)
- [SJ.US](https://longbridge.com/en/quote/SJ.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [OFAL.US](https://longbridge.com/en/quote/OFAL.US.md)
- [BNCWW.US](https://longbridge.com/en/quote/BNCWW.US.md)
- [VAPEW.US](https://longbridge.com/en/quote/VAPEW.US.md)
- [VAPE.US](https://longbridge.com/en/quote/VAPE.US.md)
- [CEADW.US](https://longbridge.com/en/quote/CEADW.US.md)
- [CEAD.US](https://longbridge.com/en/quote/CEAD.US.md)
- [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Novartis stock tanks following third major pipeline setback](https://longbridge.com/en/news/298340456.md)
- [Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline](https://longbridge.com/en/news/298303140.md)
- [iSpecimen gets Nasdaq extension to meet $2.5 million stockholders’ equity rule by Nov. 25](https://longbridge.com/en/news/298644749.md)
- [Key facts: Novartis posts late-stage failures; keeps 5-6% CAGR](https://longbridge.com/en/news/298276336.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**